We show here that the pharmacological targeting of PKCδ in CML-CD34+ cells decreased LTC-IC frequency, demonstrating that this treatment can affect the pool of CML progenitors/LSCs in vitro. This evidence concerns the gene PRKCD and chronic myelogenous leukemia, BCR-ABL1 positive.